Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cannabis Strategic Ventures (NUGS)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
833 South Spring 90014
Los Angeles, CA, US
Los Angeles, CA, US
CEO
Simon Yu
Website
cannabisstrategic.com
IPO
2009-07-24
CIK 1290504 ISIN US13765M1099
Description
Cannabis Strategic Ventures specializes in cultivating cannabis products across the United States. Beyond its growing operations, the firm actively fosters new ventures, expands existing operations, and forms strategic alliances within the broader cannabis ecosystem and its supporting sectors. Its corporate headquarters are situated in Los Angeles, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
55.8K
Beta
-31.42
Float Shares
187.46M
Free Float %
99.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +20.00% | +1,100.00% | +100.00% | +1,100.00% | -82.22% | -98.25% | -90.77% | -99.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-11.88
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-32.5% Q2'22: -98.9% (vs Q2'21)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-32.9% Q2'22: -172.2% (vs Q2'21)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-44.9% Q2'22: -4,033.2% (vs Q2'21)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-73.5% Q2'22: -3,054.9% (vs Q2'21)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-145.7% Q2'22: -145.3% (vs Q2'21)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+14.5% Q2'22: +27.9% (vs Q2'21)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-2.43× Q2'22: -2.05× (vs Q2'21)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.49M
OE per share TTM
-0.01
Owner's Yield
-1,245.31%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
112.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
1.00
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
1
+1 vs prev Q
New positions
1
Closed positions
0
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | PNC FINANCIAL SERVICES GROUP, INC. | — -1.2K (-100.0%) | — -1.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2006-01-31 | SAMSON GORDON | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-11-25 | BROWN DANE | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-09-15 | Foster Christopher G | Director / Officer | P-Purchase | A | Common shares | 3,000,000 | 0.00 | 600.00 | 3,000,000 | — | ↗ |
| 2005-09-09 | HOEGLER ROBERT | Director / Officer / 10% Owner | S-Sale | D | Common restricted shares | 12,000,000 | 4,000.00 | 48.00B | 0 | — | ↗ |
| 2005-09-09 | FLAMAN FLOYD | Director / Officer / 10% Owner | S-Sale | D | COMMON RESTRICTED SHARES | 8,000,000 | 2,000.00 | 16.00B | 0 | — | ↗ |
| 2005-09-06 | MARSHALL SCOTT | Director / Officer / 10% Owner | — | D | Common shares | 0 | 0.00 | — | 17,000,000 | — | ↗ |
| 2005-04-21 | Foster Christopher G | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-12-07 | HOEGLER ROBERT | Director / Officer / 10% Owner | — | D | Common restricted shares | 0 | 0.00 | — | 1,500,000 | — | ↗ |
| 2004-12-07 | FLAMAN FLOYD | Director / Officer / 10% Owner | — | D | COMMON RETRICTED SHARES | 0 | 0.00 | — | 1,000,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-241.3K
Shares Outstanding
187.59M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arlene Guzman | Vice President of Operations | — | female |
| Paul Hutchin | President | — | — |
| Simon Yu | Chief Executive Officer | — | male |
ESG Rating
ESG Score History
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NUGS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
